Fortress Biotech Inc  

(Public, NASDAQ:FBIO)   Watch this stock  
Find more results for NASDAQ:CNDO
+0.11 (2.86%)
May 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.80 - 3.99
52 week 1.88 - 4.42
Open 3.82
Vol / Avg. 76,864.00/202,170.00
Mkt cap 204.51M
P/E     -
Div/yield     -
EPS -1.37
Shares 50.33M
Beta 1.10
Inst. own 14%
Aug 7, 2017
Q2 2017 Fortress Biotech Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 10, 2017
Q1 2017 Fortress Biotech Inc Earnings Release
Apr 7, 2017
Fortress Biotech Inc at Biocentury Future Leaders in the Biotech Industry
Mar 16, 2017
Q4 2016 Fortress Biotech Inc Earnings Release
Mar 14, 2017
Fortress Biotech Inc at ROTH Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -32.59% -432.58%
Operating margin -39.56% -399.20%
EBITD margin - -393.00%
Return on average assets -30.53% -49.28%
Return on average equity -111.45% -115.57%
Employees 45 -
CDP Score - -


2 Gansevoort St Fl 9
NEW YORK, NY 10014-1667
United States - Map
+1-781-6524500 (Phone)
+1-781-6524545 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Fortress Biotech, Inc., formerly Coronado Biosciences, Inc., is a biopharmaceutical company. The Company is involved in the development of immunotherapy agents for the treatment of autoimmune diseases and cancer. Its sole product candidate is CNDO-109. The Company is also focused on acquiring, developing and commercializing pharmaceutical and biotechnology products. The Company's product, CNDO-109, is a lysate (disrupted Closteroviridae (CTV)-1 cells, cell membrane fragments, cell proteins and other cellular components) that activates donor Natural Killer (NK) cells. CTV-1 is a leukemic cell line re-classified as a T-cell acute lymphocytic leukemia (ALL). The Company holds the license to develop and commercialize CNDO-109 to activate NK cells for the treatment of cancer-related and other conditions, and a non-exclusive license to certain clinical data solely for use in the Investigational new drug (IND) for CNDO-109. The Company is conducting the Phase I clinical studies of CNDO-109.

Officers and directors

Lindsay A. Rosenwald M.D. Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Eric K. Rowinsky M.D. Vice Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Lucy Lu M.D. Chief Financial Officer, Executive Vice President
Age: 40
Bio & Compensation  - Reuters
Michael S. Weiss Executive Vice Chairman - Strategic Development
Age: 50
Bio & Compensation  - Reuters
George C. Avgerinos Ph.D. Senior Vice President - Biologics Operations
Age: 62
Bio & Compensation  - Reuters
Malcolm Hoenlein Ph.D. Director
Age: 72
Bio & Compensation  - Reuters
David J. Barrett CPA, Independent Director
Age: 39
Bio & Compensation  - Reuters
Jimmie Harvey Jr., M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
J. Jay Lobell J.D. Independent Director
Age: 52
Bio & Compensation  - Reuters